&

Rx&D and Canadian government partner to strengthen research

Wednesday, March 21, 2012 09:39 AM

Canada’s Research Based Pharmaceutical Companies (Rx&D) and the Canadian Institutes of Health Research (CIHR) have renewed a partnership to strengthen clinical research done in Canada, announced Leona Aglukkaq, Minister of Health.

More... »

Index Ventures launches $198 million life sciences fund

Wednesday, March 21, 2012 09:26 AM

Index Ventures, a venture capital firm, has launched its first fund solely dedicated to making investments in the life sciences sector.

More... »

Genticel completes recruitment for phase Ib HPV vaccine trial

Wednesday, March 7, 2012 06:15 AM

Genticel, a biopharmaceutical company based in Toulouse and Paris, France, has completed the recruitment of all patients participating in its phase Ib clinical trial evaluating a lyophilized formulation of ProCervix, its candidate therapeutic HPV vaccine, on adult women already infected with human papillomavirus (HPV) genotypes 16 or 18.

More... »

PRECOS appoints Dr. Martin Page scientific consultant

Thursday, March 1, 2012 06:04 AM

Preclinical Oncology Services Limited (PRECOS), a preclinical R&D service provider with a focus on oncology, has appointed Dr. Martin Page scientific consultant.

More... »

First vaccine for fatal visceral leishmaniasis enters clinical trial

Monday, February 27, 2012 10:08 AM

Seattle-based nonprofit Infectious Disease Research Institute (IDRI) has teamed up with India-based Gennova Biopharmaceuticals to target visceral leishmaniasis (VL), launching a phase I trial of vaccine for the infection disease.

More... »

J&J’s Alex Gorsky succeeds Bill Weldon as CEO

Saturday, February 25, 2012 06:34 AM

Johnson & Johnson’s board of directors has named Alex Gorsky CEO of J&J effective April 26, 2012, the date of the company’s annual meeting of shareholders.  

More... »

Intellect Neurosciences to appeal in European patent proceedings

Wednesday, February 15, 2012 03:30 PM

Intellect Neurosciences, a biopharmaceutical company focused on disease-modifying therapeutic agents for Alzheimer's disease, submitted a statement setting out its grounds for appealing the European Patent Office's (EPO) preliminary decision to revoke the company's Antisenilin (bapineuzumab) patents.

More... »

Dendreon announces CEO and chairman succession plan

Wednesday, February 1, 2012 03:41 PM

Dendreon’s board of directors has elected John H. Johnson president and CEO, succeeding Mitchell H. Gold, M.D., who has served as both for nearly a decade.

More... »

International collaboration to combat 10 neglected tropical diseases by 2020

Monday, January 30, 2012 03:49 PM

Thirteen pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organizations will join forces to eliminate or control 10 neglected tropical diseases (NTDs) by the end of the decade.

More... »

ProTrials creates U.K. subsidiary

Tuesday, January 24, 2012 10:40 AM

Sunnyvale, Calif.-based CRO ProTrials Research has created a wholly owned subsidiary to help meet its sponsors’ increasing needs for multi-national, multi-site clinical trials.  Based in the United Kingdom, ProTrials Global will help manage ongoing clinical trials in Italy, Spain and the U.K., and will be responsible for additional growth in the European arena.

More... »